Clinical Cancer Prevention pp 115-124

Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 188)

Hormone Replacement Therapy and Breast Cancer

Chapter

Abstract

There is evidence that hormone replacement therapy (HRT) may both stimulate and inhibit breast cancers, giving rise to a spectrum of activities, which are frequently hard to understand. Here we summarise the evidence for these paradoxical effects and, given the current data, attempt to give an indication where it may or may not be appropriate to prescribe HRT.

It is clear that administration of oestrogen-progestin (E-P) and oestrogen alone (E) HRT is sufficient to stimulate the growth of overt breast tumours in women since withdrawal of HRT results in reduction of proliferation of primary tumours and withdrawal responses in metastatic tumours. E-P, E including tibolone are associated with increased local and distant relapse when given after surgery for breast cancer. For women given HRT who do not have breast cancer the only large randomised trial (WHI) of E-P or E versus placebo has produced some expected and also paradoxical results. E-P increases breast cancer risk as previously shown in observational studies. Risk is increased, particularly in women known to be compliant. Conversely, E either has no effect or reduces breast cancer risk consistent with some but not all observational studies. Two observational studies report a decrease or at least no increase in risk when E-P or E are given after oophorectomy in young women with BRCA1/2 mutations. Early oophorectomy increases death rates from cardiovascular and other conditions and there is evidence that this may be reversed by the use of E post-oophorectomy. HRT may thus reduce the risk of breast cancer and other diseases (e.g., cardiovascular) in young women and increase or decrease them in older women.

References

  1. Allen E, Doisy EA (1923) An ovarian hormone. Preliminary report on its localization, extraction and partial purification and action in test animals. JAMA 81:819–821CrossRefGoogle Scholar
  2. Anderson GL, Chlebowski RT, Rossouw JE et al (2006) Prior hormone therapy and breast cancer risk in the Women’s Health Initiative randomized trail of estrogen plus progestin. Maturitas 55: 103–15Google Scholar
  3. Asselin-Labat ML, Vaillant F, Sheridan JM, et al (2010) Asselin-LabatControl of mammary stem cell function by steroid hormone signalling. Nature. 2010 Apr 11. [Epub ahead of print]Google Scholar
  4. Beral V, Million Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 352:419–427Google Scholar
  5. Bergkvist L, Adami HO, Persson I et al (1989) The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 321: 293–97PubMedCrossRefGoogle Scholar
  6. Bernstein LM, Wang P, Zheng H et al (2004) Long term exposure to tamoxifen induces sensitivity to estrdiol. Clin Cancer Res 10:1530–1534CrossRefGoogle Scholar
  7. Canfell K, Banks E, Moa AM et al (2008) Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust 188:641–644PubMedGoogle Scholar
  8. Chen WY, Manum JE, Hankinson S et al (2006) Unopposed estrogen therapy and risk of invasive breast cancer. Arch In Med 166:1027–1032Google Scholar
  9. Chlebowski RT, Hendrix SL, Langer RD et al (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trail. JAMA 289: 3243–53Google Scholar
  10. Col NF, Kim JA, Chlebowski RT (2005) Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence. Breast Cancer Res 7:R535–R540PubMedCrossRefGoogle Scholar
  11. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52, 705 women with breast cancer and 108, 411 women without breast cancer. Lancet 350:1047–1059CrossRefGoogle Scholar
  12. Cummings SR, Ettinger B, Delmas P et al (2008) The effects of tibolone in older postmenopausal women. N Engl J Med 359:697–708PubMedCrossRefGoogle Scholar
  13. Dhodapkar MV, Ingle JN, Ahmann DL (1995) Estrogen replacement therapy withdrawal and regression of metastatic breast cancer. Cancer 75:43–46PubMedCrossRefGoogle Scholar
  14. Domchek SM, Friebel TM, Neuhausen SL et al (2006) Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 7:223–229PubMedCrossRefGoogle Scholar
  15. Dubey RK, Imthurn B, Barton M et al (2005) Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen. Cardiovasc Res 66:295–306PubMedCrossRefGoogle Scholar
  16. Eisen A, Lubinski J, Gronwald J et al (2008) Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst 100:1361–1367PubMedCrossRefGoogle Scholar
  17. Ewertz M, Mellemkjaer L, Poulen AH et al (2005) Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study. Br J Cancer 92:1293–1297PubMedCrossRefGoogle Scholar
  18. Holmberg L, Iversen OE, Rudenstam CM et al (2008) Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 100:475–482PubMedCrossRefGoogle Scholar
  19. Hoover R, Gray LA Sr, Cole P et al (1976) Menopausal estrogens and breast cancer. N Engl J Med 295:401–405PubMedCrossRefGoogle Scholar
  20. Howell A, Dodwell D, Anderson H et al (1992) Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann Oncol 3:611–617PubMedGoogle Scholar
  21. Kenemans P, Bundred NJ, Foidart JM et al (2009) Safety and efficacy of tibolone in breast cancer patients with vasomotor symptoms: a double-blind randomised non-inferiority trial. Lancet Oncol 10:135–146PubMedCrossRefGoogle Scholar
  22. Kurian AW, Sigal BM, Plevritis SK (2010) Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol 28: 222–231PubMedCrossRefGoogle Scholar
  23. Lewis JS, Keeke K, Osipo C et al (2005) Intrinsic mechanism of estrdiol’induced osteoporosis in breast cancer cells resistant to estrogen deprivation. JNCI 97:1746–1759PubMedCrossRefGoogle Scholar
  24. Liu H, Lee ES, Gadjos C et al (2003) Apoptotic action of 17 beta-estradiol in raloxifene resistant MCF-7 cells in-vitro and in-vivo. JNCI 95:1586–1596PubMedCrossRefGoogle Scholar
  25. Lobo RA (2007) Surgical menopause and cardiovascular risks. Menopause 14:562–6PubMedCrossRefGoogle Scholar
  26. Madalinska JB, van Beurden M, Bleiker EM et al (2006) The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol 24:3576–3582PubMedCrossRefGoogle Scholar
  27. Marsden J, Whitehead M, A’Hern R, Baum M, Sacks N (2000) Are randomizedtrials of hormone replacement therapy in symptomatic women with breast cancer feasible? Fertil Steril 73:292–299PubMedCrossRefGoogle Scholar
  28. Marshall SF, Clarke CA, Deapen D et al (2010) Recent breast cancer incidence trends according to hormone therapy use: the California Teachers Study cohort. Breast Cancer Res 12:R4PubMedCrossRefGoogle Scholar
  29. Parker WH, Broder MS, Chang E et al (2009) Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses health study. Obstet Gynecol 113:1027–1037PubMedGoogle Scholar
  30. Prasad R, Boland GP, Cramer A et al (2003) Short-term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast cancer. Cancer 98:2539–2546PubMedCrossRefGoogle Scholar
  31. Ravdin PM, Cronin KA, Howlader N et al (2007) The decrease in breast cancer incidence in 2003 in the United States. N Engl J Med 356:1670–1674PubMedCrossRefGoogle Scholar
  32. Rebbeck TR, Friebel T, Wagner T et al (2005) Effect of short term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 23:7804–7810PubMedCrossRefGoogle Scholar
  33. Rivera CM, Grossardt BR, Rhodes DJ et al (2009) Increased cardiovascular mortality after bilateral oophorectomy. Menopause 16:15–23PubMedCrossRefGoogle Scholar
  34. Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiativerandomised controlled trial. JAMA 288:321–333PubMedCrossRefGoogle Scholar
  35. Rossouw JE, Prentice RL, Manson JE et al (2007) Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297:1465–77PubMedCrossRefGoogle Scholar
  36. Smith DC, Prentice R, Thompson DJ et al (1975) Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 293:1164–1167PubMedCrossRefGoogle Scholar
  37. Song RX, Mor G, Naftolin F et al (2001) Effect of long term oestrogen on apoptotic responses of breast cacnser cells to 17 beta-estradiol. JNCI 93:1714–1722PubMedCrossRefGoogle Scholar
  38. Stefanick ML, Anderson GL, Margolis KL et al (2006) Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295:1647–1657PubMedCrossRefGoogle Scholar
  39. The Women’s Health Initiative Steering Committee (2004) The effects of conjugated euine estrogen in postmenopausal women with hysterectomy. JAMA 291:1701–1712CrossRefGoogle Scholar
  40. Von Schoultz E, Rutqvist LE, Stockholm Breast Cancer Study Group (2005) Menopausal hormone therapy after breast cancer: the Stockholm randomised trial. J Natl Cancer Inst 97:533–535Google Scholar

Copyright information

© Springer Berlin Heidelberg 2010

Authors and Affiliations

  1. 1.Genesis Prevention CentreUniversity Hospital of South ManchesterManchesterUK

Personalised recommendations